The Department of Health and Social Care (DHSC) has extended a shortage warning for Ramipril 1.25mg capsules beyond May 29 across all four UK nations. Community pharmacies are now limited to dispensing a maximum of one month's supply per prescription, even for patients who typically receive two or three months' supply. No prescription charges apply when supplied this way.
Details of the Shortage
The warning was first issued on April 22 for Ramipril 1.25mg capsules. While Ramipril 1.25mg and 2.5mg tablets and the oral solution remain available, the DHSC warned that they cannot meet increased demand if all capsule patients switch to these forms. Patients currently taking 1.25mg capsules are urged to contact their pharmacist about tablet alternatives before stocks run low.
Impact on Patients
Ramipril is one of the top 10 prescribed drugs in the UK, used to treat hypertension and heart failure. In England alone, more than 35 million items were dispensed last year. As an ACE inhibitor, it lowers blood pressure by relaxing and widening blood vessels. Its popularity stems from its long half-life, requiring only once-daily dosing. The capsule is converted by the liver into ramiprilat, with full effects typically appearing after two to four weeks.
Recall and Supply Chain Issues
On April 20, the UK Government issued a recall for one batch of 10mg Ramipril capsules manufactured by Crescent Pharma due to a packaging error. Some cartons contained 5mg blister strips instead of 10mg. Although this was a safety issue rather than a supply issue, any recall can have a knock-on effect on the supply chain.
Resources for Patients
DHSC and NHS England have launched an online medicines supply tool, which provides up-to-date information about medicine supply issues. Patients experiencing difficulties are advised to consult their pharmacist or GP for alternative treatments.
